Neovacs SA (FR:ALNEV) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Neovacs has announced that their mRNA vaccine has shown higher efficacy in treating allergies compared to their protein vaccine in a preclinical trial with non-human primates. The company’s mRNA technology has prompted them to extend the study for long-term efficacy and prepare for a Phase I/IIa human trial. Neovacs combines R&D and investment activities, focusing on innovative immunotherapies for autoimmune diseases and allergies.
For further insights into FR:ALNEV stock, check out TipRanks’ Stock Analysis page.